Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
XBIvsPTHETF Comparison
SPDR S&P Biotech ETF (XBI) and Invesco DWA Healthcare Momentum ETF (PTH) belong to the same industry segment: US Health Care. Both ETFs have the same top 3 sector exposures: and Health Care. XBI is less expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.72% for PTH. XBI is up 3.65% year-to-date (YTD) with -$59M in YTD flows. PTH performs worse with -1.66% YTD performance, and -$2M in YTD flows. Run a side-by-side ETF comparison of XBI and PTH below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
XBI vs PTH performance and flow charts
Performance
Cumulative Flows
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XBI PTH | +1.38%-0.00% | +3.11%-3.57% | +3.65%-1.66% | +47.21%+29.38% | +63.16%+33.57% | -13.71%-9.43% |
| Flows | XBI PTH | -$4M- | -$179M-$2M | -$59M-$2M | +$90M-$12M | -$1.64B-$92M | +$1.20B-$490M |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XBI PTH | +25.68%+21.18% | +28.04%+24.52% | +27.26%+24.28% | +32.91%+25.52% |
| Max drawdown | XBI PTH | -8.19%-7.58% | -21.44%-16.12% | -32.94%-29.24% | -57.63%-50.10% |
| Max drawdown duration | XBI PTH | 48d87d | 141d183d | 331d271d | 1822d1651d |
XBI | PTH | |
Last sale 3/12/2026 at 2:09 PM | $124.15 | $48.80 |
| Previous close 03/11/2026 | $126.38 | $49.20 |
| Consolidated volume 03/11/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
XBI | PTH | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
XBI | PTH | |
|---|---|---|
| Last price | $124.15 | $48.80 |
| 1D performance | -1.76% | -0.81% |
| AuM | $8.10 B | $121.25 M |
| E/R | 0.35% | 0.72% |
XBI | PTH | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | SPDR | Invesco |
| Benchmark | S&P Biotechnology Select Industry Index | Dorsey Wright Healthcare Technical Leaders Index |
| N° of holdings | 123 | 46 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | January 31, 2006 | October 12, 2006 |
| ESG | No | No |
Countries
Sectors
Diversification
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Top 15 holdings
How have the XBI and PTH ETFs performed in 2026?
As of March 11, 2026, XBI is up 3.65% year-to-date (YTD), while PTH has lost -1.66%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: XBI or PTH?
Year-to-date, the XBI ETF saw -$59M in flows, compared to -$2M for PTH.
Which ETF is more volatile: XBI or PTH?
Over the past year, XBI had a volatility of 28.04%, while PTH experienced 24.52%.
Which ETF is bigger: XBI or PTH?
As of March 11, 2026, XBI holds $8.10 B in assets under management (AUM), while PTH manages $121.25 M.
What sectors do the XBI and PTH ETFs invest in?
XBI leans toward sectors like Health Care. Meanwhile, PTH focuses on Health Care.
What are the top holdings of the XBI ETF and PTH ETF?
XBI top holdings include MODERNA INC, MIRUM PHARMACEUTICALS INC and REVOLUTION MEDICINES INC. PTH holds in its top three: US74006W2070, GUARDANT HEALTH INC and ROIVANT SCIENCES LTD.
Which ETF is more diversified: XBI or PTH?
XBI holds 149 securities with 21.6% of its assets in the top 15. PTH has 58 securities and a top 15 weight of 50.37%.
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
Are Biotechnology ETFs In the Midst of a Comeback?
Continued tightening of the U.S. labor market
Two biotech ETFs to watch for the rest of 2022 and beyond
Biotech ETFs – Investing in Health Innovation
Biotech ETFs – Investing in Health Innovation
Calamos Investments Powers the Next Phase of the Autocallable Revolution
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
